Voyager Therapeutics, Inc. (VYGR)
1.83
+0.05
(+2.81%)
USD |
NASDAQ |
Nov 03, 16:00
1.835
0.00 (0.00%)
After-Hours: 20:00
Voyager Therapeutics Enterprise Value : 28.36M for Nov. 3, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 03, 2026 | 28.36M |
| November 02, 2026 | 25.30M |
| October 30, 2026 | 21.62M |
| October 29, 2026 | 24.07M |
| October 28, 2026 | 28.97M |
| October 27, 2026 | 22.23M |
| October 26, 2026 | 23.46M |
| October 23, 2026 | 22.84M |
| October 22, 2026 | 30.20M |
| October 21, 2026 | 40.00M |
| October 20, 2026 | 50.42M |
| October 19, 2026 | 41.84M |
| October 16, 2026 | 32.65M |
| October 15, 2026 | 42.45M |
| October 14, 2026 | 39.39M |
| October 13, 2026 | 47.97M |
| October 12, 2026 | 55.32M |
| October 09, 2026 | 66.35M |
| October 08, 2026 | 61.45M |
| October 07, 2026 | 67.57M |
| October 06, 2026 | 66.96M |
| October 05, 2026 | 66.96M |
| October 02, 2026 | 66.35M |
| October 01, 2026 | 80.14M |
| September 30, 2026 | 80.44M |
| Date | Value |
|---|---|
| September 29, 2026 | 77.99M |
| September 28, 2026 | 81.67M |
| September 25, 2026 | 80.44M |
| September 24, 2026 | 87.79M |
| September 23, 2026 | 92.08M |
| September 22, 2026 | 108.63M |
| September 21, 2026 | 104.95M |
| September 18, 2026 | 105.56M |
| September 17, 2026 | 102.50M |
| September 16, 2026 | 103.11M |
| September 15, 2026 | 105.56M |
| September 14, 2026 | 111.69M |
| September 11, 2026 | 111.69M |
| September 10, 2026 | 111.69M |
| September 09, 2026 | 115.37M |
| September 08, 2026 | 124.56M |
| September 04, 2026 | 131.30M |
| September 03, 2026 | 123.33M |
| September 02, 2026 | 133.14M |
| September 01, 2026 | 126.40M |
| August 31, 2026 | 127.62M |
| August 28, 2026 | 133.14M |
| August 27, 2026 | 128.24M |
| August 26, 2026 | 128.24M |
| August 25, 2026 | 129.46M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Lineage Cell Therapeutics, Inc. | 205.79M |
| Armata Pharmaceuticals, Inc. | 404.78M |
| Black Diamond Therapeutics, Inc. | 10.44M |
| Invivyd, Inc. | 19.71M |
| Elicio Therapeutics, Inc. | 23.96M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -24.47M |
| Revenue (Quarterly) | 3.165M |
| Total Expenses (Quarterly) | 27.64M |
| EPS Diluted (Quarterly) | -0.4042 |
| Gross Profit Margin (Quarterly) | 71.31% |
| Profit Margin (Quarterly) | -773.2% |
| Earnings Yield | -99.09% |
| Normalized Earnings Yield | -99.09 |